| Typicality: | 0.325 |
| Saliency: | 0.176 |
| on the safety benefits | 4 | other |
| on pharmacokinetics | 2 | other |
| about this strategy | 2 | other |
| trial → provide → further data | 5 |
| trial → provide → additional data | 4 |
| negative | neutral | positive |
| 0.010 | 0.658 | 0.332 |
| Raw frequency | 9 |
| Normalized frequency | 0.176 |
| Modifier score | 0.500 |
| Perplexity | 116.535 |